News
Plasseraud IP alongside Caelus Life Sciences in a European patent enforcement victory
Our Partner and Head of the Amsterdam office, Johan Renes, assisted Caelus Life Sciences in proceedings resulting in a preliminary injunction against Pendulum and iHerb, based on Caelus’s European patent EP 2 753 187.
At stake? Protecting a key microbiome innovation. The patent covers the use of a specific gut bacterium at the core of Caelus’s platform for cardiometabolic health. Following a preliminary assessment of validity and infringement, the Court ordered Pendulum and iHerb to cease certain activities involving the products concerned in the countries covered by the order.
The order was issued in summary proceedings and is therefore provisional. Caelus will now initiate proceedings on the merits before the Unified Patent Court (UPC). Pendulum and iHerb may appeal, but the order remains in force pending any appeal.
A strong reminder that innovation needs protection. Patents play a crucial role in safeguarding scientific breakthroughs and the investment behind years of research and development.
Caelus Life Sciences was founded in 2014 by award-winning scientists and pioneers in microbiome research. The company develops microbiome-based ingredients that originate from the human gut. Its work combines strain discovery, clinical research, regulatory development, intellectual property and industrial-scale production to turn next-generation beneficial microbes into safe, scientifically substantiated and partner-ready products.
Congratulations to Caelus on this important milestone in protecting its technology and defending its intellectual property rights!
More information: European court grants preliminary injunction against Pendulum and iHerb based on Caelus patent
